[Plasma proteins in patients with liver steatosis and the effect of treatment of essential phospholipids].
BACKGROUND
Steatosis of the liver is the most frequent diffuse disturbance of liver parenchyma. Accumulation of fat droplets in hepatocytes determine the damage of function of subcellular structures and energy metabolism of liver cells. The damagables include functions also the synthesis of phospholipids which are required for the correct function of membranes. Essentiale forte is a mixture of choline phosphatides with high content of polyenic carboxylic acids. In our study we were interested in the effect of administration of the drug Essentiale forte to patients with liver steatosis.


METHODS
An open clinical trial was performed in 29 patients (15 men and 14 women) suffering from liver steatosis. Two capsules of Essentiale forte (Rhone-Poulenc Rorer) were administered 3 times daily for 3 months. Individual biochemical parameters were determined each month.


RESULTS
The therapeutic effect of the substance on the patient's well-being and the clinical condition was assessed as being good in 23 patients (76%). There was a significant improvement in parameters of hepatocyte integrity (aminotransferases) and a decrease of activity of gamma-glutamyltransferase in sera of patients after therapy. In the group of acute phase proteins there was a significant decrease in the alpha-1-acid glycoprotein level. A similar tendency was also in the level of haptoglobin. In the group of the parameters of proteosynthetic function of the liver (albumin, transferrin, prealbumin) there was no change. Statistically significant decreases were detected also in the levels of immunoglobulins G and M.


CONCLUSIONS
The submitted findings confirm positive effect of essential phospholipids on the treatment of liver steatosis. (Fig. 4, Ref. 15.).
Turecký
L
L
Ustav lekárskej chémie, biochémie a klinickej biochémie Lekárskej fakulty Univerzity Komenského v Bratislave, Slovakia.
Kupcová
V
V
Szántová
M
M
Laktis
K
K
Uhlíková
E
E
D001798:Blood Proteins / Q000032:analysis*; D005234:Fatty Liver / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*
D001798:Blood Proteins; D010713:Phosphatidylcholines; C011246:essential 303 forte